Evgen Pharma (GB:TCF) has released an update.
Evgen Pharma has announced a strategic financial move, granting options over nearly 29 million ordinary shares to key employees and management as part of their Long Term Incentive Plan. This decision comes after the acquisition of Chronos Therapeutics and is designed to align the interests of the management team and shareholders, with the management team forgoing cash bonuses in favor of share-based payments. The new option grants will vest over time, with a portion available immediately to former Chronos personnel, who are subject to an 18-month lock-in period for share sales.
For further insights into GB:TCF stock, check out TipRanks’ Stock Analysis page.
